Lineage Cell Therapeutics, Inc. · Healthcare · Biotechnology
Scores & Status Key
AI Summary Scores: Intraday / Swing / Long scores are synthesized from multi-factor analysis for each timeframe. They summarize current conditions discussed in the report and do not constitute trading recommendations.
Intraday Trend Score: A 0–100 composite from the Trend Explorer™ analytics engine used for ranking and comparison. It describes current conditions and is not a forecast.
Trend Status: A rules-based label (Bullish / Mixed / Bearish) derived from signal confluence (trend structure, momentum, and positioning). It indicates alignment, not expected return.
Last
$1.68
+$0.04 (+2.13%) 11:24 AM ET
Prev closePrevC$1.64
OpenOpen$1.66
Day highHigh$1.69
Day lowLow$1.64
VolumeVol323,039
Avg volAvgVol1,177,481
On chart
Interval
Intervals apply to 1D & 5D.
Intervals apply to 1D & 5D.
Scale: Linear
Overlays
Panels
Style
Scale: Linear
Presets
Tools
Tickers only (no ^ indexes). Add up to 5.
Mkt cap
$408.50M
P/E ratio
-5.98
FY Revenue
$14.56M
EPS
-0.28
Gross Margin
99.75%
Sector
Healthcare
AI report sections
BULLISH
LCTX
Lineage Cell Therapeutics, Inc.
Lineage Cell Therapeutics shows very strong 12‑month price appreciation alongside ongoing operating losses and negative free cash flow, indicating a market that is pricing in future potential rather than current profitability. Technical indicators point to moderately constructive momentum with recent bullish pattern signals, but elevated valuation multiples and high short interest with long days-to-cover underscore notable risk. The balance sheet features high liquidity and minimal debt, while recent news flow around longevity and cell-therapy themes has been predominantly positive.
AI summarized at 11:07 AM ET, 2026-04-15
AI summary scores
INTRADAY:56SWING:52LONG:38
Volume vs average
Intraday (cumulative)
+63% (Above avg)
Vol/Avg: 1.63×
RSI
55.29(Neutral)
Neutral (40–60)
0255075100
MACD momentum
Intraday
-0.00 (Weak)
MACD: 0.01 Signal: 0.01
Short-Term
+0.02 (Strong)
MACD: -0.02 Signal: -0.04
Long-Term
+0.01 (Strong)
MACD: -0.05 Signal: -0.06
Intraday trend score
59.80
LOW59.80HIGH59.80
Latest news
LCTX•12 articles•Positive: 6Neutral: 1Negative: 1
PositiveBenzinga• Usa News Group
Biotechs Racing to Translate Longevity Science Into Real Therapies -- And One Microcap Company Is Producing An Anti-Aging Protein From Genetically Modified, Encapsulated Cells
The longevity biotech market is expanding rapidly, projected to grow from $9.86 billion in 2025 to $29.7 billion by 2034. Multiple companies are advancing cell and gene therapies targeting age-related diseases: Lineage Cell Therapeutics is developing islet therapy for Type 1 diabetes, Ocugen reported 46% lesion reduction in age-related macular degeneration, Vertex is advancing stem cell-derived islet therapy toward regulatory submissions, and Longeveron published positive Phase 2b data for age-related frailty treatment.
Company is expanding its AlloSCOPE platform into Type 1 diabetes islet therapy and achieved a milestone with Roche's Genentech collaboration for geographic atrophy treatment, demonstrating pipeline expansion in age-related diseases.
NeutralBenzinga• Equity-Insider.Com
A Key "Master" Protein That Declines by Half After Age 40. One Company Found a Way to Restore It.
Avaí Bio announced it has initiated manufacturing of a Master Cell Bank of genetically modified cells that overexpress the α-Klotho protein, a key anti-aging protein that naturally declines by 50% after age 40. The milestone represents a transition from research to production infrastructure for their Klothonova anti-aging platform using Cell-in-a-Box® encapsulation technology. The cell therapy sector is rapidly expanding, with the global market projected to grow from $10.4 billion to over $45 billion by 2035.
AVAILCTXMESOLGVNα-Klotho proteincell therapyanti-agingMaster Cell Bank
Sentiment note
Mentioned as a competitor advancing allogeneic cell therapies with proprietary manufacturing platform, but no specific news or developments disclosed in this article.
The healthcare sector is experiencing a structural shift toward regenerative medicine and longevity infrastructure, valued at $27 trillion by 2030. Several biotech companies are advancing cell therapy and gene-targeted treatments: Avant Technologies presented cell encapsulation technology for diabetes at a European symposium, MannKind received FDA label updates for Afrezza inhaled insulin, Altimmune gained FDA Breakthrough Therapy Designation for pemvidutide in liver disease, Lineage Cell Therapeutics received a gene-edited cell line from Factor Bioscience, and Arrowhead Pharmaceuticals initiated a Phase 1/2a trial for a dual-gene silencing RNAi therapeutic for cardiovascular disease.
Received delivery of a novel gene-edited hypoimmune cell line from Factor Bioscience with disease-specific edits, expanding the company's cell therapy platform capabilities and supporting development of superior product candidates.
NegativeThe Motley Fool• Jesterai
W.P. Carey (WPC) Q2 AFFO Jumps 9.4%
W.P. Carey, a diversified net lease REIT, reported Q2 2025 earnings with strong revenue growth and AFFO per share, despite experiencing net income decline due to non-cash market adjustments. The company raised full-year guidance and increased quarterly dividend.
WPCLCTXREITearningsreal estatenet leasedividend
Sentiment note
Mentioned in context of a $69.0 million mark-to-market loss on an equity holding, indicating potential financial challenges
Refrigerated Warehousing Market Revenues to Grow from $85 Billion in 2024 to $241 Billion by 2030 - Led by Lineage, Conestoga Cold Storage, Americold Logistics, NewCold Cooperatief UA, and Tippmann Group
The global refrigerated warehousing market is expected to grow significantly, driven by the surge in e-commerce, particularly in the grocery and food sectors, as well as advancements in cold storage technologies and the rising demand for temperature-sensitive products.
The article mentions Lineage as one of the key players in the refrigerated warehousing market, indicating its prominent position in the industry.
PositiveGlobeNewswire Inc.• Orbcomm
ORBCOMM joins Move to -15°C coalition to promote cold chain sustainability
ORBCOMM has joined the Move to -15°C campaign as a technology provider to help track and share the telematics data that will help quantify the initiative's impact. The Move to -15°C is a coalition of industry leaders committed to changing the global temperature that frozen food is stored and transported at from -18°C to -15°C, which could cut carbon emissions by 17.7 million metric tonnes and reduce energy consumption by 25 terawatt-hours.
LCTXHPGLYclimate actiongreenhouse gas emissionsenergy consumptionsupply chain costsfrozen foodtemperature standards
Sentiment note
Lineage is mentioned as one of the stakeholders in the Move to -15°C coalition, indicating its commitment to supporting the initiative and its goals.
PositiveThe Motley Fool• Courtney Carlsen
W.P. Carey: Buy, Sell, or Hold?
W.P. Carey has undergone a transformation by restructuring its real estate portfolio to make its business more resilient. The company sold off its office properties and reset its dividend, allowing it to reinvest capital into higher-quality income-producing properties. With a focus on industrial and warehouse properties, W.P. Carey is well-positioned to benefit from the ongoing demand for e-commerce and distribution centers.
W.P. Carey holds a sizable investment in the cold storage real estate investment trust (REIT) Lineage, which is valued at around $405 million. The article suggests that W.P. Carey could cash in on this stake and have even more capital to reinvest in income-producing properties.
PositiveInvesting.com• Reuters
Cold storage REIT Lineage aims to raise up to $3.85 billion in US IPO By Reuters - Investing.com
Cold storage giant Lineage is seeking to raise up to $3.85 billion in its initial public offering on the Nasdaq Global Select Market. The real estate investment trust is backed by private equity firm Bay Grove Capital.
LCTXcold storageREITIPONasdaq
Sentiment note
Lineage is seeking to raise a significant amount of capital through its IPO, indicating growth and expansion plans.
UnknownMarketWatch• MarketWatch
The Russell 2000 Index has soared, but you might be better off looking elsewhere for quality small-cap stocks
A more selective small-cap index has consistently outperformed the Russell 2000
IWMIJRSPYVIR
UnknownBenzinga• Avi Kapoor
Lineage Cell Therapeutics, Longeveron And 2 Other Stocks Under $2 Insiders Are Buying
The Dow Jones index closed higher by around 25 points on Tuesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform.
Airship AI Holdings
The Trade: Airship AI Holdings, Inc. (NASDAQ: AISP) Director, CEO and Chairman of the BOD Victor Huang acquired a total of 60,000 shares an average price of $1.92. To acquire these shares, it cost around $114,917.
What’s Happening: Airship AI recently started delivery of $10.9 million U.S. government contracts for advanced video and sensor management.
What Airship AI Holdings Does: Airship ...
UnknownZacks Investment Research• Zacks Equity Research
Lineage (LCTX) Up 10% on Upbeat Data From Eye Disease Study
Lineage (LCTX) rises 10% on positive imaging analyses results from the phase I/IIa study of OpRegen in patients with geographic atrophy secondary to age-related macular degeneration.
CORTLCTXBTTX
UnknownBenzinga• Lisa Levin
Why DLocal Shares Are Trading Higher By 25%; Here Are 20 Stocks Moving Premarket
Gainers
Novo Integrated Sciences, Inc. (NASDAQ: NVOS) shares surged 40.9% to $0.1635 in pre-market trading. Novo Integrated Sciences issued an update on certain current actions and events. The company recently reported a year-over-year increase in third-quarter EPS results.
EBET, Inc. (NASDAQ: EBET) rose 34.9% to $0.0560 in pre-market trading after jumping 22% on Tuesday.
DLocal Limited (NASDAQ: DLO) shares climbed 25.1% to $19.39 in pre-market trading after the company reported better-than-expected financial results for its second quarter and reaffirmed FY23 revenue guidance.
Precision BioSciences, Inc. (NASDAQ: DTIL) shares gained 24.8% to $0.6620 in pre-market trading after the company completed strategic transaction with Imugene for Azer-Cel in cancer.
T2 Biosystems, Inc. (NASDAQ: TTOO) shares rose 20.1% to $0.7101 in pre-market trading after jumping over 51% on Tuesday.
STRATA Skin Sciences, Inc. (NASDAQ: SSKN) shares gained 19.4% to $0.6798 in pre-market trading. The company recently posted downbeat quarterly results.
The Alkaline Water Company Inc. ...
GBNHEBETDLOCOHRNewsPenny StocksSmall CapPre-Market Outlook
News and sentiment labels describe article tone and are provided for research purposes only. They are not trading recommendations or forecasts.
Trade Ranks App
Trade Ranks, LLC is not a registered investment adviser or broker-dealer. All rankings and AI reports are for informational and educational purposes only and are not personalized advice. Investing involves risk. Policy Portal